Pfizer, a US pharmaceutical company, is likely to submit an application for approval of a COVID-19 vaccination booster for teenagers between the ages of 16 and 17 this week. The Washington Post reported on Tuesday that Pfizer and its partner BioNTech are set to submit an application to the US Food and Drug Administration in the coming days to obtain approval for their booster shot for that age range, citing anonymous sources familiar with the issue. According to the sources, the US regulators are expected to provide their approval in a short period of time.
Currently, US persons 18 and older who have received their second dose of the Pfizer-BioNTech or Moderna vaccinations are eligible for booster shots six months after receiving their first dose. Americans were also permitted to acquire a booster shot from Johnson & Johnson as soon as two months after receiving the single-shot vaccine. The newest initiative to broaden the eligibility for booster doses among teenagers came against the backdrop of the White House’s ongoing debate about the new Omicron COVID-19 form of the virus. Earlier on Monday, US Vice President Joe Biden urged people to get immunized and to arrange booster shots as soon as possible. Additionally, he stated that the shots were “the best protection against this new variation or any of the variants that are now available.”
Gretchen Johnson: Biography, Career, Net Worth & Latest Facts
In the aftermath of the discovery of the Omicron variation, Pfizer also stated on Friday that it intends to research and develop an improved version of its existing COVID-19 vaccine before launching it. If the new B.1.1.529 variation, which was discovered for the first time in South Africa, is confirmed to be resistant to the current coronavirus vaccination, the US manufacturer claims that it can modify its coronavirus vaccine in roughly 100 days. In addition, the business stated that it is currently evaluating the current vaccinations to determine their efficiency against the Omicron virus.
